ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed …
Over the last 12 months, insiders at ADMA Biologics, Inc. have bought $0 and sold $26.52M worth of ADMA Biologics, Inc. stock.
On average, over the past 5 years, insiders at ADMA Biologics, Inc. have bought $4.75M and sold $13.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 130,000 shares for transaction amount of $482,144 was made by Grossman Jerrold B (director) on 2023‑08‑30.
2024-11-22 | Sale | President and CEO | 48,967 0.0205% | $21.10 | $1.03M | -7.32% | ||
2024-11-22 | Sale | CFO and Treasurer | 15,000 0.0063% | $21.15 | $317,250 | -7.32% | ||
2024-09-09 | Sale | director | 9,000 0.0039% | $18.47 | $166,189 | +5.79% | ||
2024-08-30 | Sale | COO and SVP, Compliance | 24,150 0.0101% | $16.90 | $408,050 | +11.61% | ||
2024-08-29 | Sale | director | 136,861 0.0589% | $17.27 | $2.36M | +12.20% | ||
2024-08-27 | Sale | President and CEO | 389,356 0.1665% | $17.29 | $6.73M | +11.04% | ||
2024-08-26 | Sale | President and CEO | 236,889 0.103% | $17.69 | $4.19M | +10.02% | ||
2024-08-23 | Sale | director | 60,000 0.0255% | $18.26 | $1.1M | +4.13% | ||
2024-06-14 | Sale | President,CEO, and Interim CFO | 100,000 0.044% | $10.72 | $1.07M | +68.25% | ||
2024-03-19 | Sale | director | 411,829 0.1772% | $6.08 | $2.5M | +114.70% | ||
2024-03-18 | Sale | director | 49,887 0.0221% | $6.01 | $299,821 | +122.64% | ||
2024-03-15 | Sale | director | 183,008 0.0805% | $6.01 | $1.1M | +119.70% | ||
2024-03-14 | Sale | director | 448,276 0.1906% | $6.05 | $2.71M | +117.94% | ||
2024-03-13 | Sale | director | 407,000 0.1776% | $6.21 | $2.53M | +108.95% | ||
2023-08-30 | director | 130,000 0.0588% | $3.71 | $482,144 | +44.74% | |||
2023-08-24 | director | 25,000 0.0108% | $3.90 | $97,500 | +36.05% | |||
2023-08-22 | Sale | director | 1.43M 0.637% | $3.87 | $5.54M | +35.92% | ||
2023-08-18 | Sale | President and CEO | 250,000 0.1139% | $4.15 | $1.04M | +27.07% | ||
2023-08-16 | Sale | President and CEO | 3 <0.0001% | $4.38 | $13 | +16.78% | ||
2023-08-16 | Sale | EVP, CFO | 178,184 0.0804% | $4.45 | $793,400 | +16.78% |
Grossman Adam S | President and CEO | 1989007 0.8414% | $17.40 | 37 | 7 | <0.0001% |
Grossman Jerrold B | director | 467305 0.1977% | $17.40 | 17 | 1 | <0.0001% |
KWON YOUNG | director | 241441 0.1021% | $17.40 | 2 | 1 | +57.32% |
Guiheen Lawrence P. | director | 153941 0.0651% | $17.40 | 5 | 1 | <0.0001% |
PERCEPTIVE ADVISORS LLC | 10 percent owner | 13262375 5.6104% | $17.40 | 3 | 9 | <0.0001% |
BlackRock | $120.12M | 7.85 | 18.2M | +1.57% | +$1.86M | <0.01 | |
The Vanguard Group | $83.75M | 5.47 | 12.69M | -1.57% | -$1.34M | <0.01 | |
State Street | $69.65M | 4.55 | 10.55M | +11.28% | +$7.06M | <0.01 | |
Nuveen | $69.06M | 4.51 | 10.46M | -7.87% | -$5.9M | 0.02 | |
Invesco | $51.51M | 3.37 | 7.8M | +27.69% | +$11.17M | 0.01 |